The challenge of managing adrenocortical carcinoma: two case studies
Kanjanapan, Yada; Prasanna, Thiru; Perampalam, Sumathy; Yip, Desmond
Adrenocortical carcinoma is a rare entity affecting 1–2 people per million. It has a relatively poor prognosis, with an overall 5-year survival of 20–45%. The reasons include a high risk of recurrence following resection and relatively poor response to cytotoxic treatment. The use of the adrenalytic mitotane as adjuvant therapy is supported by level III evidence from cohort studies. In the metastatic setting, one randomized controlled trial provides level II evidence for a three-drug...[Show more]
|Collections||ANU Research Publications|
|Source:||International Journal of Endocrine Oncology|
|The challenge of managing adrenocortical carcinoma.pdf||1.63 MB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator